Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3)
: Mummery, C. J.; Börjesson-Hanson, A.; Blackburn, D. J.; Vijverberg, E. G. B.; De Deyn, P. P.; Ducharme, S.; Jonsson, M.; Schneider, A.; Rinne, J. O.; Ludolph, A. C.; Bodenschatz, R.; Kordasiewicz, H.; Swayze, E. E.; Fitzsimmons, B.; Mignon, L.; Moore, K. M.; Yun, C.; Baumann, T.; Li, D.; Norris, D.A.; Crean, R.; Graham, D. L.; Huang, E.; Ratti, E.; Bennett, C. F.; Junge, C.; Lane, R. M.
Publisher: Nature Research
: 2024
Nature Medicine
: Nature Medicine
: 304
: 30
: 1078-8956
: 1546-170X
DOI: https://doi.org/10.1038/s41591-023-02639-3
: https://www.nature.com/articles/s41591-023-02639-3
: https://research.utu.fi/converis/portal/detail/Publication/181983815
